Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice
Maria Agustina Battistone, … , Dennis Brown, Sylvie Breton
Maria Agustina Battistone, … , Dennis Brown, Sylvie Breton
Published April 14, 2020
Citation Information: J Clin Invest. 2020;130(7):3734-3749. https://doi.org/10.1172/JCI134791.
View: Text | PDF
Research Article Inflammation Nephrology

Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice

  • Text
  • PDF
Abstract

Ischemic acute kidney injury (AKI), a complication that frequently occurs in hospital settings, is often associated with hemodynamic compromise, sepsis, cardiac surgery, or exposure to nephrotoxins. Here, using a murine renal ischemia/reperfusion injury (IRI) model, we show that intercalated cells (ICs) rapidly adopted a proinflammatory phenotype after IRI. Wwe demonstrate that during the early phase of AKI either blockade of the proinflammatory P2Y14 receptor located on the apical membrane of ICs or ablation of the gene encoding the P2Y14 receptor in ICs (a) inhibited IRI-induced increase of chemokine expression in ICs, (b) reduced neutrophil and monocyte renal infiltration, (c) reduced the extent of kidney dysfunction, and (d) attenuated proximal tubule damage. These observations indicate that the P2Y14 receptor participates in the very first inflammatory steps associated with ischemic AKI. In addition, we show that the concentration of the P2Y14 receptor ligand UDP-glucose (UDP-Glc) was higher in urine samples from intensive care unit patients who developed AKI compared with patients without AKI. In particular, we observed a strong correlation between UDP-Glc concentration and the development of AKI in cardiac surgery patients. Our study identifies the UDP-Glc/P2Y14 receptor axis as a potential target for the prevention and/or attenuation of ischemic AKI.

Authors

Maria Agustina Battistone, Alexandra C. Mendelsohn, Raul German Spallanzani, Andrew S. Allegretti, Rachel N. Liberman, Juliana Sesma, Sahir Kalim, Susan M. Wall, Joseph V. Bonventre, Eduardo R. Lazarowski, Dennis Brown, Sylvie Breton

×

Figure 4

IRI induces the renal recruitment of proinflammatory immune cells, and this process is attenuated by PPTN.

Options: View larger image (or click on image) Download as PowerPoint
IRI induces the renal recruitment of proinflammatory immune cells, and t...
(A) Flow cytometry analysis of renal recruitment of live CD45+ immune cells (pink boxes) 2 hours after IRI compared with SHAM. SHM-DMSO (n = 6), IRI-DMSO (n = 8), IRI-PPTN (n = 8); *P = 0.037, **P = 0.004, ****P < 0.0001. (B) Renal recruitment of live neutrophils (CD45+CD11b+Ly6G+) relative to the live renal cell population (pink boxes) 2 hours after IRI compared with SHAM. SHM-DMSO (n = 8), IRI-DMSO (n = 7), IRI-PPTN (n = 8); **P = 0.0013, ***P = 0.0001, ****P < 0.0001. (C) Renal recruitment of live monocytes (CD45+CD11b+Ly6C+Ly6G–) relative to the live renal cell population (pink boxes) 2 hours after IRI compared with SHAM (n = 8 mice in each group). *P = 0.048, ***P = 0.0002. (D) Renal recruitment of live neutrophils (CD45+CD11b+Ly6G+) relative to the renal live cell population 24 hours (left, pink boxes) and 48 hours after IRI compared with SHAM. SHM 24 hours DMSO (n = 7), SHM 24 hours PPTN (n = 7), SHM 48 hours DMSO (n = 6), SHM 48 hours PPTN (n = 6), IRI 24 hours DMSO (n = 7), IRI 24 hours PPTN (n = 6), IRI 48 hours DMSO (n = 11), IRI 48 hours PPTN (n = 10); *P = 0.04, **P = 0.0057, ****P < 0.0001. (E) Renal recruitment of live monocytes (CD45+CD11b+Ly6C+Ly6G–) relative to the live renal cell population 24 hours (left, pink boxes) and 48 hours after IRI compared with SHAM. SHM 24 hours DMSO (n = 7), SHM 24 hours PPTN (n = 6), SHM 48 hours DMSO (n = 6), SHM 48 hours PPTN (n = 6), IRI 24 hours DMSO (n = 6), IRI 24 hours PPTN (n = 6), IRI 48 hours DMSO (n = 11), IRI 48 hours PPTN (n = 10). *P = 0.039, ****P < 0.0001. In all bar graphs, data are means ± SEM, and each dot represents 1 mouse. (A–C) One-way ANOVA and Tukey’s post hoc test. (D and E) Two-way ANOVA and Tukey’s test.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts